Cipla Limited 

is an Indian multinational pharmaceutical company, headquartered in Mumbai,

India. Cipla primarily develops medicines to treat respiratory, cardiovascular
disease, arthritis, diabetes, weight control and depression; other medical conditions.

Cipla was founded by Khwaja Abdul Hamied as 'The Chemical, Industrial

& Pharmaceutical Laboratories' in 1935 in Mumbai. The name of the company was changed to
'Cipla Limited' on 20 July 1984. In the year 1985, the US FDA approved the company's bulk drug
manufacturing facilities. Led by the founder's son Yusuf Hamied, a Cambridge-educated
chemist, the company provided generic AIDS and other drugs to treat poor people in the
developing world. In 1995, Cipla launched Deferiprone, the world's first oral iron chelator. In
2001, Cipla offered medicines (antiretrovirals) for HIV treatment at a fractional cost (less than
$350 per year per patient).

In 2013 Cipla acquired the South African company Cipla-Medpro, kept it as a subsidiary, and
changed its name to Cipla Medpro South Africa Limited. At the time of the acquisition Cipla-
Medpro had been a distribution partner for Cipla and was South Africa's third biggest
pharmaceutical company. The company had been founded in 2002 and was known as Enaleni
Pharmaceuticals Ltd. In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a
joint venture between Cipla and Medpro Pharmaceuticals, a South African generics
company, and in 2008 it changed its name to Cipla-Medpro.

Cipla, as an organization has been built brick-by-brick on the foundation of care. Caring for Life
has always been and continues to remain, our guiding purpose. Driven by the same purpose,
we have extended our presence to 80+ countries providing over 1,500 products across various
therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we
are deepening our presence in the key markets of India, South Africa, and the U.S. among other
economies of the emerging world.
For over eight decades, making a difference to patients has inspired every aspect of Cipla’s
work. Cipla paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a
dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing
inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible
corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of
Caring for Life and deep-rooted community links wherever it is present, make it a partner of
choice for global health bodies and stakeholders.

Cipla over 1500 products in 65 therapeutic categories available in over 50 dosage forms. These
capabilities range from the development of a simple molecule to highly complex multi-chiral
centers molecule with a distinction of affordability and highest quality. Our capacities include
our own facilities and in licensed facilities which support both generic and the biotech business.
Cipla investments in manufacturing capital include development of new drug delivery systems,
facilitation of infrastructure supporting API and formulation developments and strengthening of
platform technologies.

Cipla commenced commercial production at our state-of-the-art manufacturing unit for

formulations at Sikkim II. Cipla also ensured the formulation manufacturing of existing facilities
at Indore and Goa to service increasing demand across markets. Additionally, company
commissioned an extra manufacturing capacity of 10 Metric Tonnes/year specifically for
Oncology API at Bommasandra in Bengaluru along with commissioning a pilot facility for
micro/flow reactor at Kurkumbh as a step towards continuous manufacturing process. Besides
the new facility, all the existing facilities are upgraded